CHENIX (chenodiol) by Leadiant Biosciences is (chenodeoxycholic acid) is a primary bile acid, synthesized from cholesterol in the liver. Approved for cerebrotendinous xanthomatosis (ctx) in adults. First approved in 1983.
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
CHENIX (chenodiol) is an oral small-molecule bile acid replacement therapy indicated for cerebrotendinous xanthomatosis (CTX), a rare genetic disorder caused by sterol 27-hydroxylase deficiency. It works by restoring deficient endogenous chenodeoxycholic acid levels, activating farnesoid X receptor (FXR) and suppressing atypical bile acid and bile alcohol accumulation. CHENIX addresses a critical unmet need in a small, genetically defined patient population.
As LOE approaches with established generic competition, the brand team is likely consolidating commercial operations and shifting to patient support and specialty pharmacy focus.
(chenodeoxycholic acid) is a primary bile acid, synthesized from cholesterol in the liver. In CTX, the major bile acid synthesis pathways are disrupted due to partial or total deficiency in sterol 27-hydroxylase encoded by the CYP27A1 gene. CTEXLI may act to replace deficient levels of the…
Worked on CHENIX at Leadiant Biosciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Leadiant Biosciences is hiring 1 role related to this product
CHENIX careers are heavily concentrated in Commercial functions, with only 1 linked job opening and director-level roles dominating the hiring profile. Working on CHENIX offers experience managing rare disease commercialization, specialty pharmacy channels, and patient identification in a low-volume, high-margin therapeutic area—skills valuable in orphan drug portfolios but with limited growth trajectory as LOE approaches.
1 open roles linked to this drug